AtaiBeckley Inc (ATAI)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$7.350.00%
Close 2026-09-11 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
Research Workspace
Put ATAI beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Management is running behind on a stated commitment.
View ThesisManagement screens weak on earnings delivery, margins.
View ManagementExpectations look high — what the market is pricing in runs ahead of what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskATAI is unprofitable with weak recent financial performance. Management is unsteady with frequent disruptive corporate change. The company trades in a supportive healthcare sector backdrop. No earnings release is on record to confirm a growth trajectory. The desk lacks a valuation bridge to compare peer multiples. Our model puts the next-quarter miss probability near 46%. Management is running behind on a stated commitment. The thesis is on watch. This read is provisional.
Trailing returns as of 2026-09-11. ATAI is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 14 analysts currently covering ATAI (as of Sep 2026).
Based on 5 Wall Street analysts offering 12-month price targets for ATAI in the last 4 months.
Continue this research
Compare ATAI with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| ATAI Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 0 valuation methods, at three horizons. As of 2026-11-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put ATAI next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Complete acquisition by Eli Lilly in 2026
Acquisition completion aligns with management's objective.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-11. EPS is implied from price ÷ P/E. Not investment advice.
Current $7.35
The last 12 months of price, then the range of analyst 12-month targets from today’s $7.35.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Phase 3 launch is a significant catalyst.